ChemicalBook > Product Catalog >Biochemical Engineering >Enzymes And Coenzymes drugs >Reteplase


Reteplase Suppliers list
Company Name: Dideu Industries Group Limited
Tel: 029-88380327; 17691182729
Products Intro: Product Name:Reteplase USP/EP/BP
Purity:99.9% Package:25kgs/Drum;200kgs/Drum Remarks:FDA GMP CEP Approved Manufacturer
Company Name: LGM Pharma  
Tel: 1-(800)-881-8210
Products Intro: Product Name:Reteplase
Purity:Typically NLT 98%
Company Name: Beijing HuaMeiHuLiBiological Chemical   
Tel: 010-56205725;010-86181995
Products Intro: Product Name:Reteplase
Purity:99% Package:25kg
Company Name: Lanospharma Laboratories Co.,Ltd  
Tel: 13440048448
Products Intro:
Reteplase Basic information
Product Name:Reteplase
Synonyms:Reteplase;Retavase;Reteplase USP/EP/BP
Product Categories:
Mol File:Mol File
Reteplase Structure
Reteplase Chemical Properties
Safety Information
MSDS Information
Reteplase Usage And Synthesis
DescriptionReteplase was launched in Germany and the US for acute myocardial infarction. Retevase is a single chain recombinant form of tissue plasminogen activator (t-PA) with all except the kringle-2 and protease domains deleted. When expressed in E. coli the inactive form is produced and stored in inclusion bodies. After purification and an in vitro refolding process the active form is obtained. The expression in E. coli gives rise to a non-glycosylated protein. This and the deletion of several domains allows reteplase to have a longer half-life and a slower clearance. Despite the deletions and refolding the catalytic center remains intact. The kringle-2 domain allows binding to lysine in fibrin which makes it effective for the rapid and complete lysis of coronary thrombi. While it does not have a high affinity for binding to fibrin, its activity is stimulated by it and has the same level of in vivo fibrin selectivity as human t-PA. It has a low affinity for endothelial cells and can be administered as a double bolus injection. Netaplase, a similar recombinant form of t- PA, was launched by MitsuiIMochida in Japan.
OriginatorBoehringer Mannheim (Germany)
UsesMyocardial infarction therapy; plasminogen activator.
Brand nameRetavase
General DescriptionReteplase (Retavase) is a deletion mutant variant of tPAthat is produced in recombinant E. coli. The deletions arein domains responsible for half-life, fibrin affinity, andthrombolytic potency. It consists of the kringle-2 domain and protease domain of tPA but lacks the kringle-1 domainand the growth factor domain. It is considered a thirdgenerationthrombolytic agent and has a mechanism of actionsimilar to that of alteplase. Reteplase acts directly bycatalyzing the cleavage of plasminogen and initiatingthrombolysis. It has high thrombolytic potency.
Mechanism of actionReteplase is a recombinant deletion mutant of tPA lacking the finger, epidermal growth factor, kringle 1 domain, and carbohydrate side chain. As a highly fibrin-specific thrombolytic agent, reteplase is missing the first 172 amino acids that are present in alteplase and has 355 amino acids with a molecular weight of 39 kDa. Because of the removal of the finger kringle 1 domain, reteplase binding to fibrin is reduced from that of alteplase, and reteplase has reduced fibrin selectivity. In addition, the structural modification reduces hepatic elimination, leading to a longer half-life (reteplase, 14–18 minutes; alteplase, 3–4 minutes).
Clinical UseAdministered as a double bolus of 10 U every 30 minutes, reteplase is approved for use in acute myocardial infarction.
Reteplase Preparation Products And Raw materials
Tag:Reteplase(133652-38-7) Related Product Information
Orlistat Phenytoin sodium Pipecuronium bromide Dehydroepiandrosterone Nedaplatin Anistreplasa [INN-Spanish] Rivaroxaban Paclitaxel Urokinase Nattokinase Alteplase